An open-label, 6-month study of allopurinol safety in gout: The LASSO study.
about
Treatment approaches and adherence to urate-lowering therapy for patients with gout.Current and future therapies for gout.Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjectsLesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial.Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study).Lesinurad: A Review in Hyperuricaemia of Gout.Lesinurad Combined With Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol (a US-Based Study).Gout: An old disease in new perspective - A review.Management of gout in the real world: current practice versus guideline recommendations.Anti-Gouty Arthritis and Antihyperuricemia Effects of Sunflower (Helianthus annuus) Head Extract in Gouty and Hyperuricemia Animal Models.Drug-Induced Kidney Injury in the Elderly.An analytical comparison between point-of-care uric acid testing meters.The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized controlled trial.Pilot study of a multidisciplinary gout patient education and monitoring program.Evaluation of Pharmacokinetic Interactions Between Lesinurad, a New Selective Urate Reabsorption Inhibitor, and Commonly Used Drugs for Gout Treatment.Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study.Accuracy of the HumaSensplus point-of-care uric acid meter using capillary blood obtained by fingertip puncture.Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label study.Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese and non-Asian male subjects.ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout
P2860
Q33597442-C258E1F3-86C8-41F4-893C-76524FA630A1Q38660829-A3EEC3A1-3D3A-45E0-A730-1B147F63ECACQ38661431-332E3445-CB09-4FC9-9A5C-53D64E32950FQ38734760-8A81F102-490A-4F4B-9320-8C9611642E21Q39207518-9E5B70AE-9DC7-433B-B583-DC684B72328DQ39251437-592A657C-6888-4664-90BC-CAEEC47EBC54Q39450920-C121501A-4CEA-4191-82C1-2E09595FE513Q40106739-1725557F-54D8-4675-AE0B-87BAD78CBECBQ40291328-A1C0B17F-3FAD-4B6B-8474-D9CC51EC4C0AQ41448685-138A9493-46C4-4216-A4D5-C410B3C0A304Q45065480-93ED7618-D268-4E98-BE51-B2561975C8F4Q45984119-D61D0F72-80C6-4C61-8515-6304D61B9F9EQ47099047-7F5F3DEF-2F2D-4D8D-BB29-9F6EA5729ADDQ50111167-89762A04-D4E6-4BD4-8951-7C457339C066Q53583024-AC30D6AB-9DC1-489A-842E-F24BBBD88DD4Q53837944-415866B6-C173-4D84-99A5-04D3B60889C3Q55262503-195BE764-8B70-4031-A4C4-077011C4882FQ55286574-1EFBD12D-5B0A-4475-BEA6-12A4D4D2B1D2Q55334448-F3CCE414-AB81-4A00-B6D4-CB12ABE1C4B2Q57154626-5A1ABE18-510B-46B4-9D1B-2AF7B9D91A21
P2860
An open-label, 6-month study of allopurinol safety in gout: The LASSO study.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
An open-label, 6-month study of allopurinol safety in gout: The LASSO study.
@en
type
label
An open-label, 6-month study of allopurinol safety in gout: The LASSO study.
@en
prefLabel
An open-label, 6-month study of allopurinol safety in gout: The LASSO study.
@en
P2093
P1476
An open-label, 6-month study of allopurinol safety in gout: The LASSO study.
@en
P2093
Chris Storgard
David Fitz-Patrick
Hyon K Choi
Matt Cravets
Michael A Becker
Scott Baumgartner
P304
P356
10.1016/J.SEMARTHRIT.2015.05.005
P577
2015-05-21T00:00:00Z